Mats Jerkeman

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

M. Dreyling, Elı́as Campo, Olivier Hermine et al. · Annals of Oncology · 2017 · 732 citations · Full text

Lymphoid Neoplasia, Mantle Cell Lymphoma, Medicine +4

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2008 · 619 citations · Full text

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 456 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Refractory Mantle-cell Lymphoma +7

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

Fredrik Ellin, Jenny Landström, Mats Jerkeman et al. · Blood · 2014 · 389 citations

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen et al. · Blood · 2017 · 383 citations · Full text